AEMD - Aethlon Medical, Inc.
| Previous Close | 2.4200 |
| Open | 2.4199 |
| Bid | 0.0000 x 900 |
| Ask | 0.0000 x 900 |
| Day's Range | 2.2600 - 2.9000 |
| 52 Week Range | 2.0500 - 25.6500 |
| Volume | 71,554 |
| Avg. Volume | 26,864 |
| Market Cap | 4.1M |
| Beta (3Y Monthly) | 0.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
Here's Why We Worry About Aethlon Medical's (NASDAQ:AEMD) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- Zacks Small Cap Research
AEMD: IDE Approved. Hemopurifier U.S. Clinical Cancer Program On-Deck…
By Brian Marckx, CFA NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT When Aethlon Medical (NASDAQ:AEMD) reported fiscal Q1 2020 financial results in August, management noted that they anticipated imminent filing of an Investigational Device Exemption (IDE) seeking approval to initiate U.S.-based clinical studies for their Hemopurifier device in cancer patients. Not only did that filing
- Simply Wall St.
How Much Of Aethlon Medical, Inc. (NASDAQ:AEMD) Do Insiders Own?
If you want to know who really controls Aethlon Medical, Inc. (NASDAQ:AEMD), then you'll have to look at the makeup of...
- Market Exclusive
Market Morning: Prorogation Ruled Rogue, High Demand for Fed Repo, New Breast Cancer Tests
British High Court Rules Against Johnson Parliament Prorogation Apparently, proroguing Parliament was not Boris Johnson’s prerogative. The British high court ruled today that the Prime Minister acted unlawfully in suspending Parliament until October 14th, and that he misled the Queen in advising that Parliament should be suspended. Johnson is now facing calls to resign, which […]The post Market Morning: Prorogation Ruled Rogue, High Demand for Fed Repo, New Breast Cancer Tests appeared first on Market Exclusive.
- Zacks Small Cap Research
AEMD: SeaStar Collaboration Is Intriguing, More Evidence of Exosomes’ Role in Cancer Progression
Aethlon Medical (AEMD) reported financial results for their fiscal fourth quarter ending March 31, 2019 and provided a business update. Revenue of $80k was recorded in the quarter, representing the initial payment under AEMD’s ongoing NCI grant (The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation), which was awarded in September 2018 and will pay a total of $298.4k through ~August 2019. This revenue relates to a completed milestone, “to evaluate Hemopurifier-mediated capture of breast cancer exosomes”.
- Simply Wall St.
How Financially Strong Is Aethlon Medical, Inc. (NASDAQ:AEMD)?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Aethlon Medical, Inc. (NASDAQ:AEMD) is a small-cap stock with a market capitalization of US$16m. While investors primarily fo...
- Zacks Small Cap Research
AEMD: Eventual FDA Cancer Indication Is A Realistic Outcome
Aethlon (AEMD) reported financial results for their fiscal third quarter ending December 31st and provided a business update. While we had modeled an initial payment under their ongoing NCI grant (The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation), which was awarded in September and will pay a total of $298.4k through ~August 2019, initial revenue is now expected to be recognized in the current (i.e.
